Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 13/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986595 | 0.85 | NPBWR1 (0.36) | NPBWR1MCHR1 | |
| SCHEMBL31524249 | 0.82 | THRB (0.35) | NPBWR1MCHR1 | |
| SCHEMBL29497476 | 0.70 | NPBWR1 (0.32) | NPBWR1MCHR1 | |
| SCHEMBL20444062 | 0.67 | KDM5B (0.48) | NPBWR1GAA | |
| SCHEMBL16448707 | 0.66 | RAB9A (0.37) | NPBWR1GAA | |
| SCHEMBL19723234 | 0.66 | KAT2B (0.36) | — | |
| SCHEMBL2621556 | 0.64 | ALDH1A1 (0.38) | — | |
| SCHEMBL30578650 | 0.63 | NPBWR1 (0.38) | NPBWR1MCHR1 | |
| SCHEMBL20444069 | 0.63 | GAA (0.46) | NPBWR1GAA | |
| SCHEMBL12806392 | 0.62 | CYP1A2 (0.44) | ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138971-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | ROYAL PHARMA (IN) | 2026-05-21 | — | — | US | claimed |
| WO-2024084491-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | MEHTA NILESH VIPINCHANDRA (IN) | 2024-04-25 | — | — | WO | claimed |
| US-20260138971-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | ROYAL PHARMA (IN) | 2026-05-21 | — | — | US | disclosed |
| US-20260138971-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | ROYAL PHARMA (IN) | 2026-05-21 | — | — | US | disclosed |
| WO-2024084491-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | MEHTA NILESH VIPINCHANDRA (IN) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024084491-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | MEHTA NILESH VIPINCHANDRA (IN) | 2024-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138971-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | CARM1, DAO, CA2 | NPBWR1 2541/4885MCHR1 2307/4885GAA 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.